Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This trial is a Phase I/II study in which a combination of duvelisib and nivolumab will be
used to treat a total of patients diagnosed with advanced unresectable melanoma who have
progressed on anti-PD1 therapy. The Recommended Phase II Dose of oral duvelisib will be
determined and administered with intravenous nivolumab 480mg for up to 1 year or until the
patient's disease does not progress or the patient experiences unacceptable side effects to
treatment.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
John Kirkwood
Collaborators:
Bristol-Myers Squibb Secura Bio, Inc. Verastem, Inc.